PT-141 (Bremelanotide): Innovations in Sexual Dysfunction Research
Sexual dysfunction remains a widespread and multifactorial clinical concern, affecting both men and women across diverse age groups. Traditional therapeutic approaches—such as phosphodiesterase type 5 (PDE5) inhibitors—primarily act on peripheral mechanisms by enhancing vascular response. However, they often fail to address the central neurological pathways involved in sexual desire and arousal. In recent years, PT-141 […]